

**Corporate Medical Policy:** Rituximab (Rituxan®) and Rituximab Biosimilars for the Treatment of Non-Oncologic Indications “Notification”  
**POLICY EFFECTIVE OCTOBER 1, 2026**

**Restricted Product(s):**

- \*rituximab (Rituxan®) intravenous infusion for administration by a healthcare professional
- \*\*\*rituximab-arrx (Riabni®) intravenous infusion for administration by a healthcare professional
- \*\*\*rituximab-pvvr (Ruxience®) intravenous infusion for administration by a healthcare professional
- \*\*\*rituximab-abbs (Truxima®) intravenous infusion for administration by a healthcare professional
- \*Any other approved rituximab biosimilars

**\*\*\*preferred agent(s)**

**\*non-preferred agent(s)**

**FDA Approved Use:**

- For the treatment of moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate in adults who have had an inadequate response to one or more TNF antagonist therapies
- For the treatment of granulomatosis with polyangiitis (GPA) (Wegener’s granulomatosis) and microscopic polyangiitis (MPA) in combination with glucocorticoids in adult and pediatric patients 2 years of age and older
- For the treatment of moderate to severe pemphigus vulgaris (PV) in adults

**Criteria for Medical Necessity:**

**The restricted product(s) may be considered medically necessary for covered when the following criteria are met:**

1. If the request is for rituximab (Rituxan) or a non-preferred rituximab biosimilar product, ONE of the following:
  - a. The patient has tried and had an inadequate response to ALL of the following preferred rituximab biosimilar products: rituximab-arrx (Riabni), rituximab-pvvr (Ruxience), AND rituximab-abbs (Truxima) **[medical record documentation required]; OR**
  - b. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ALL preferred rituximab biosimilar products (i.e., rituximab-arrx [Riabni], rituximab-pvvr [Ruxience], AND rituximab-abbs [Truxima]) that is NOT expected to occur with the requested product **[medical record documentation required]; OR**

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

- c. The patient has a documented serious adverse event that required medical intervention to ALL preferred rituximab biosimilar products (i.e., rituximab-arxx [Riabni], rituximab-pvvr [Ruxience], AND rituximab-abbs [Truxima]) that is NOT anticipated with the requested product **[medical record documentation required]; AND**
  - i. The prescriber has completed and submitted an FDA MedWatch Adverse Event Reporting Form **[medical record documentation required]; AND**
- 2. ONE of the following:
  - a. The patient has a diagnosis of moderately to severely active **rheumatoid arthritis (RA); AND**
    - i. The patient is 18 years of age or older; **AND**
    - ii. ONE of the following:
      - 1. The patient has tried and had an inadequate response to maximally tolerated methotrexate (e.g., titrated to 25 mg weekly) for at least 3-months **[medical record documentation required]; OR**
      - 2. The patient has tried and had an inadequate response to another conventional agent (i.e., hydroxychloroquine, leflunomide, sulfasalazine) used in the treatment of RA for at least 3-months **[medical record documentation required]; OR**
      - 3. The patient has an intolerance or hypersensitivity to ONE of the following conventional agents (i.e., maximally tolerated methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) used in the treatment of RA **[medical record documentation required]; OR**
      - 4. The patient has an FDA labeled contraindication to ALL of the following conventional agents (i.e., methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) used in the treatment of RA **[medical record documentation required]; AND**
    - iii. ONE of the following:
      - 1. The patient will be taking the requested agent in combination with methotrexate; **OR**
      - 2. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to methotrexate **[medical record documentation required]; AND**
    - iv. ONE of the following:
      - 1. The patient has tried and had an inadequate response to at least ONE biologic immunomodulator FDA labeled or supported in compendia for the treatment of RA for at least 3-months **[medical record documentation required]; OR**
      - 2. The patient has an intolerance or hypersensitivity to ONE biologic immunomodulator FDA labeled or supported in compendia for the treatment of RA **[medical record documentation required]; OR**

3. The patient has an FDA labeled contraindication to ALL biologic immunomodulators FDA labeled for the treatment of RA **[medical record documentation required]; OR**
- b. The patient has a diagnosis of **granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or microscopic polyangiitis (MPA)** [subtypes of ANCA-associated vasculitis]; **AND**
  - i. The patient is 2 years of age or older; **AND**
  - ii. ONE of the following:
    1. The patient will receive the requested agent in combination with glucocorticoids (e.g., prednisone, methylprednisolone, etc.) **[medical record documentation required]; OR**
    2. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ALL glucocorticoids (e.g., prednisone, methylprednisolone, etc.) used in the treatment of GPA or MPA **[medical record documentation required]; OR**
- c. The patient has a diagnosis of moderate to severe **pemphigus vulgaris (PV)**; **AND**
  - i. The patient is 18 years of age or older; **OR**
- d. The patient has a diagnosis of **autoimmune hemolytic anemia (AIHA)**; **AND**
  - i. The patient has warm-reactive disease; **AND**
    1. The patient is refractory to or dependent on glucocorticoids (e.g., prednisone) **[medical record documentation required]; OR**
  - ii. The patient has cold agglutinin disease; **AND**
    1. The diagnosis has been confirmed by ALL of the following tests **[medical record documentation required]**:
      - a. Chronic hemolysis; **AND**
      - b. Positive polyspecific direct antiglobulin test (DAT); **AND**
      - c. Positive monospecific DAT specific for C3d; **AND**
      - d. Cold agglutinin titer  $\geq 64$  at 4°C; **AND**
      - e. IgG DAT  $\leq 1+$ ; **AND**
    2. The patient has symptomatic anemia, transfusion-dependence, and/or disabling circulatory symptoms **[medical record documentation required]; OR**
- e. The patient has a diagnosis of **chronic immune (idiopathic) thrombocytopenia (ITP, Evans syndrome)**; **AND**

- i. ONE of the following **[medical record documentation required]**:
    - 1. The patient has a platelet count  $\leq 30 \times 10^9/L$ ; **OR**
    - 2. The patient has a platelet count  $< 50 \times 10^9/L$  AND has symptomatic bleeding and/or an increased risk for bleeding (e.g.,  $\geq 60$  years old, on anticoagulant or antiplatelet medications, history of bleeding, comorbidities for bleeding [e.g., peptic ulcer disease, uncontrolled hypertension, anemia or low hemoglobin], etc.); **AND**
  - ii. ONE of the following:
    - 1. The patient has tried and had an inadequate response to a prior ITP treatment (i.e., glucocorticoids [prednisone, dexamethasone], immunoglobulins [IVIG or anti-D], thrombopoietin receptor agonists [avatrombopag, eltrombopag, romiplostim], or splenectomy) **[medical record documentation required]; OR**
    - 2. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ALL other ITP treatment (i.e., glucocorticoids [prednisone, dexamethasone], immunoglobulins [IVIG or anti-D], thrombopoietin receptor agonists [avatrombopag, eltrombopag, romiplostim], and splenectomy) **[medical record documentation required]; OR**
- f. The patient has a diagnosis of **immune-mediated or acquired thrombotic thrombocytopenic purpura (iTTP)**; **AND**
- i. The diagnosis has been confirmed by severely reduced baseline activity of ADAMTS13 (less than 10%), with the presence of an ADAMTS13 inhibitor or anti-ADAMTS13 IgG **[medical record documentation required]; AND**
  - ii. ONE of the following:
    - 1. BOTH of the following:
      - a. The requested agent will be used in combination with therapeutic plasma exchange (TPE); **AND**
      - b. ONE of the following:
        - i. The requested agent will be used in combination with glucocorticoids used in the treatment of iTTP **[medical record documentation required]; OR**
        - ii. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to glucocorticoids used in the treatment of iTTP **[medical record documentation required]; OR**
    - 2. The patient is in remission and will be using the requested agent for prevention of relapse; **OR**
- g. The patient has a diagnosis of a relapsing form of **multiple sclerosis (MS)**, to include clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; **AND**
- i. The patient will NOT be using the requested agent in combination with an additional disease modifying agent (DMA) used in the treatment of MS; **OR**

- h. The patient has a diagnosis of **neuromyelitis optica spectrum disorder (NMOSD)**; **AND**
  - i. ONE of the following **[medical record documentation required]**:
    - 1. The patient is seropositive for aquaporin-4 (AQP4) IgG antibodies; **OR**
    - 2. The patient is seronegative for AQP4-IgG antibodies OR has unknown AQP4-IgG antibody status; **AND**
  - ii. The diagnosis has been confirmed by the presence of the following core clinical characteristics – at least ONE for AQP4-IgG antibody seropositive patients or at least TWO for AQP4-IgG antibody seronegative patients or patients with unknown AQP4-IgG antibody status **[medical record documentation required]**:
    - 1. Optic neuritis; **OR**
    - 2. Acute myelitis; **OR**
    - 3. Area postrema syndrome: Episode of otherwise unexplained hiccups or nausea and vomiting; **OR**
    - 4. Acute brainstem syndrome; **OR**
    - 5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions; **OR**
    - 6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions; **AND**
  - iii. The patient has had at least ONE attack or relapse in the last 12 months prior to treatment with an immunotherapy or complement inhibitor for NMOSD (e.g., an eculizumab product, inebilizumab, ravulizumab, a rituximab product, satralizumab, etc.) **[medical record documentation required]**; **AND**
  - iv. The patient does NOT have any other alternative diagnoses to explain or cause the current disease symptoms (e.g., multiple sclerosis, ischemic optic neuropathy, etc.); **AND**
  - v. The patient will NOT be using the requested agent in combination with another biologic immunomodulator agent used in the treatment of NMOSD (e.g., an eculizumab product, inebilizumab, ravulizumab, satralizumab, etc.); **OR**
- i. The patient has a diagnosis of **immunoglobulin G4-related disease (IgG4-RD)**; **AND**
  - i. The diagnosis has been confirmed by the 2019 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria for IgG4-RD (i.e., fulfillment of entry criteria, lack of any exclusion criteria, and  $\geq$  20 classification criteria inclusion points) **[medical record documentation required]**; **AND**
  - ii. The patient has IgG4-RD affecting two or more organs/sites at any time in the course of disease (e.g., pancreas, major salivary glands, lacrimal glands, bile ducts/biliary tree, orbits, kidneys, lungs, aorta, retroperitoneum, pachymeninges, thyroid gland [Riedel's thyroiditis]) **[medical record documentation required]**; **AND**
  - iii. The patient does NOT have any other alternative diagnoses to explain or cause the current disease symptoms (e.g., malignancy, infection, other autoimmune disorders, etc.); **AND**

- iv. The patient is experiencing or has recently experienced an IgG4-RD flare that requires initiation or continuation of glucocorticoid treatment, and/or the patient has recurrent disease **[medical record documentation required]; AND**
- v. ONE of the following:
  - 1. The patient has tried and had an inadequate response to glucocorticoids (e.g.,  $\geq 1$  flare, new or worsening symptoms, no reduction in mass/organ size, no improvement in organ function, inadequate decreases in serum IgG4 concentrations from glucocorticoids alone) used in the treatment of IgG4-RD **[medical record documentation required]; OR**
  - 2. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to glucocorticoids used in the treatment of IgG4-RD **[medical record documentation required]; AND**
- vi. The patient will NOT be using the requested agent in combination with inebilizumab-cdon (Uplizna) used in the treatment of IgG4-RD; **OR**
- j. The patient has a diagnosis of **refractory generalized myasthenia gravis (gMG); AND**
  - i. The patient has a positive serological test for anti-muscle-specific tyrosine kinase (MuSK) antibodies **[medical record documentation required]; AND**
  - ii. ONE of the following:
    - 1. The prescriber has assessed the patient's current medications and discontinued any medications known to exacerbate myasthenia gravis (e.g., beta blockers, procainamide, quinidine, magnesium, anti-programmed death receptor-1 monoclonal antibodies, hydroxychloroquine, aminoglycosides); **OR**
    - 2. The prescriber has provided clinical rationale indicating that discontinuation of the offending agent is not clinically appropriate **[medical record documentation required]; AND**
  - iii. ONE of the following:
    - 1. The patient has tried and had an inadequate response to at least ONE conventional agent used in the treatment of gMG (i.e., glucocorticoids, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide) **[medical record documentation required]; OR**
    - 2. The patient has an intolerance or hypersensitivity to ONE conventional agent used for the treatment of gMG (i.e., glucocorticoids, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide) **[medical record documentation required]; OR**
    - 3. The patient has an FDA labeled contraindication to ALL conventional agents used for the treatment of gMG (i.e., glucocorticoids, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide) **[medical record documentation required]; OR**

4. The patient required chronic intravenous immunoglobulin (IVIG) (i.e., at least every 3 months over 12 months without symptom control) **[medical record documentation required]; OR**
5. The patient required chronic plasmapheresis/plasma exchange (i.e., at least every 3 months over 12 months without symptom control) **[medical record documentation required]; AND**
- iv. The patient will NOT be using the requested agent in combination with other immunotherapy or complement inhibitors (e.g., eculizumab products [e.g., Soliris, Bkembv, Epysqli], efgartigimod alfa [Vyvgart, Vyvgart Hytrulo], immunoglobulins, nipocalimab [Imaavy], ravulizumab [Ultomiris], rozanolixizumab [Rystiggo], or zilucoplan [Zilbrysq]) used in the treatment of gMG; **OR**
- k. The patient has a diagnosis of **systemic lupus erythematosus (SLE); AND**
  - i. The patient has a clinical diagnosis of moderate to severe SLE **[medical record documentation required]; AND**
    1. The patient does NOT have active lupus nephritis (LN); **AND**
  - ii. The patient has autoantibody-positive SLE (e.g., presence of anti-nuclear antibodies [ANA], double stranded DNA antibodies [anti-dsDNA], anti-Smith antibodies [anti-Sm], etc.) **[medical record documentation required]; AND**
  - iii. The patient has active disease while on standard therapy for SLE (e.g., corticosteroids, anti-malarials [hydroxychloroquine, chloroquine], mycophenolic acid analogs, non-steroidal anti-inflammatory drugs [NSAIDs], non-biologic immunosuppressants [azathioprine, methotrexate, cyclosporine, oral cyclophosphamide]) alone or as combination therapy **[medical record documentation required]; AND**
  - iv. ONE of the following:
    1. The patient will be receiving the requested agent in combination with hydroxychloroquine **[medical record documentation required]; OR**
    2. The patient has an FDA labeled contraindication or intolerance to hydroxychloroquine **[medical record documentation required]; AND**
  - v. The patient does NOT have severe active central nervous system (CNS) lupus; **AND**
  - vi. The patient will NOT be using the requested agent in combination with voclosporin (Lupkynis) used in the treatment of SLE; **OR**
- l. The patient has a diagnosis of **lupus nephritis (LN); AND**
  - i. The patient has a clinical diagnosis of SLE **[medical record documentation required]; AND**
  - ii. The patient has biopsy-proven active Class III, IV, and/or Class V LN **[medical record documentation required]; AND**

- iii. The patient will be receiving the requested agent in combination with a standard immunosuppressive therapy regimen for active LN (e.g., azathioprine, cyclophosphamide, glucocorticoids, mycophenolic acid analogs, etc.) **[medical record documentation required]; AND**
- iv. ONE of the following:
  - 1. The patient will be receiving the requested agent in combination with hydroxychloroquine **[medical record documentation required]; OR**
  - 2. The patient has an FDA labeled contraindication or intolerance to hydroxychloroquine **[medical record documentation required]; AND**
- v. The patient does NOT have severe active central nervous system (CNS) lupus; **AND**
- vi. The patient will NOT be using the requested agent in combination with voclosporin (Lupkynis) used in the treatment of LN; **OR**
- m. The patient has a diagnosis of **idiopathic (primary) membranous nephropathy; AND**
  - i. The patient does NOT have any other alternative diagnoses to explain or cause the current disease symptoms (e.g., infections, autoimmune diseases, malignancies, nutritional supplements [e.g., lipoic acid, etc.], nonsteroidal anti-inflammatory drugs [NSAIDs], etc.); **AND**
  - ii. The requested agent will be used for ONE of the following indications **[medical record documentation required]**:
    - 1. First-line therapy in patients with ANY of the following moderate to high risk factors for progressive disease:
      - a. Proteinuria greater than 3.5 g/day and no decrease greater than 50% after 6 months of therapy with an angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB); **OR**
      - b. eGFR less than 60 mL/min/1.73m<sup>2</sup>; **OR**
      - c. Proteinuria greater than 8 g/day for greater than 6 months; **OR**
      - d. The patient has experienced serious complications of nephrotic syndrome (e.g., acute kidney injury, infection, thromboembolic events, etc.); **OR**
    - 2. Initial disease relapse following remission on first-line therapy with a rituximab product, a calcineurin inhibitor (e.g., tacrolimus, cyclosporine, etc.) or cyclophosphamide in combination with glucocorticoids; **OR**
    - 3. Treatment-resistance to first-line therapy with a rituximab product, a calcineurin inhibitor (e.g., tacrolimus, cyclosporine, etc.) or cyclophosphamide in combination with glucocorticoids; **AND**
      - a. The patient has a stable eGFR; **AND**
      - b. The requested agent will be used in combination with a calcineurin inhibitor if previously treated with a rituximab product alone in the first-line setting; **OR**

4. Disease recurrence following kidney transplant; **AND**
  - a. The patient has proteinuria greater than 1 g/day; **OR**
- n. The patient has a diagnosis of **pediatric idiopathic nephrotic syndrome**; **AND**
  - i. The patient is less than 18 years of age; **AND**
  - ii. The patient has symptomatic disease (i.e., nephrotic-range proteinuria [ $>3.5$  g/day] and either hypoalbuminemia [ $<3.5$  g/dL] or edema when albumin level is not available); **AND**
  - iii. The patient has been diagnosed with ONE of the following **[medical record documentation required]**:
    1. Frequently relapsing nephrotic syndrome (FRNS) with at least three relapses per year or at least two relapses within 6 months following remission of the initial episode; **OR**
    2. Steroid-dependent nephrotic syndrome (SDNS) with two consecutive relapses during steroid therapy (either at full-dose or during tapering) or within 14 days of discontinuation of steroid therapy; **OR**
    3. Steroid-resistant nephrotic syndrome (SRNS) with failure to achieve complete remission within a 4-week course of daily corticosteroids; **AND**
  - iv. ONE of the following:
    1. The patient has tried and had an inadequate response to an adequate trial of at least ONE other steroid-sparing agent (e.g., cyclophosphamide, calcineurin inhibitor [e.g., tacrolimus, cyclosporine, etc.], mycophenolate mofetil, etc.) **[medical record documentation required]; OR**
    2. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ALL other steroid-sparing agents (e.g., cyclophosphamide, calcineurin inhibitor [e.g., tacrolimus, cyclosporine, etc.], mycophenolate mofetil, etc.) used in the treatment of pediatric idiopathic nephrotic syndrome **[medical record documentation required]; OR**
- o. The patient has a diagnosis of **Wiskott-Aldrich syndrome (WAS)**; **AND**
  - i. The requested agent will be used as pretreatment prior to infusion of etuvetidigene autotemcel (Waskyra) **[medical record documentation required]; AND**
  - ii. The requested agent will be used for ONE of the following:
    1. To deplete autoreactive B-cells; **OR**
    2. As pre-emptive treatment for potential lymphoproliferative disorder due to Epstein Barr Virus infection; **OR**
- p. The patient has a diagnosis of **antisynthetase syndrome-related interstitial lung disease (ASyS-ILD)**; **AND**
  - i. The patient is 18 years of age or older; **AND**

- ii. The patient has antisyntetase antibody positive disease (e.g., anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, etc.) **[medical record documentation required]; AND**
- iii. The diagnosis has been confirmed by the presence of characteristic features of interstitial lung disease (ILD) on chest high-resolution computed tomography (HRCT); **AND**
- iv. The prescribing physician has assessed baseline disease severity using an objective measure (i.e., baseline glucocorticoid use, pulmonary function testing [i.e., forced vital capacity (FVC%), total lung capacity (TLC%), diffusing capacity of the lungs for carbon monoxide (DLCO%)], or chest HRCT scan); **AND**
- v. The patient has severe active disease **[medical record documentation required]; AND**
- vi. The patient has recurrent or progressive disease despite treatment with glucocorticoids and/or other immunosuppressive agents (e.g., azathioprine, mycophenolate mofetil, cyclophosphamide, tacrolimus, etc.) **[medical record documentation required]; AND**
- vii. ONE of the following:
  - 1. The requested agent will be used in combination with glucocorticoids or other immunosuppressive agents (e.g., azathioprine, mycophenolate mofetil, cyclophosphamide, tacrolimus, etc.) **[medical record documentation required]; OR**
  - 2. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ALL glucocorticoids and immunosuppressive agents used in the treatment of ASyS-ILD **[medical record documentation required]; AND**
- 3. The prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist for PV; hematologist for AIHA, ITP, TTP, WAS; immunologist for RA, GPA, MPA, PV, gMG, MS, NMOSD, SLE, LN, WAS; nephrologist for RA, GPA, MPA, SLE, LN, membranous nephropathy, pediatric nephrotic syndrome; neurologist for RA, GPA, MPA, gMG, MS, NMOSD, SLE, LN; pulmonologist for GPA, MPA, ASyS-ILD; rheumatologist for RA, GPA, MPA, ASyS-ILD, IgG4-RD, gMG, MS, NMOSD, SLE, LN, membranous nephropathy, pediatric nephrotic syndrome; etc.) or has consulted with a specialist in the area of the patient's diagnosis; **AND**
- 4. The patient will NOT be using the requested agent in combination with another biologic immunomodulator agent used in the treatment of the requested indication; **AND**
- 5. The patient does NOT have any FDA labeled contraindications to the requested agent; **AND**
- 6. The patient has been screened for hepatitis B infection measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) AND if positive the patient has begun therapy for hepatitis B; **AND**
- 7. The requested quantity does NOT exceed the maximum units allowed for the duration of approval (see table below); **AND**
- 8. For requests for injection or infusion administration of the requested medication in an **inpatient or outpatient hospital setting**, Site of Care Criteria applies (outlined below)\*

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

**Duration of Approval:**

Wiskott-Aldrich syndrome: 180 days (6 months); one-time, single-dose treatment per lifetime

All other diagnoses: 365 days (1 year)

**Note: This policy only applies to rituximab (Rituxan) and rituximab biosimilars (Riabni, Ruxience, and Truxima) when used for the treatment of non-oncologic indications.**

| FDA Label Reference                               |                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                            |       |                                                                               |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------------------------------------------------------------------------|
| Medication                                        | Indication                                                                                          | Dosing                                                                                                                                                                                                                                                                                                                                                                                                     | HCPCS | Maximum Units*                                                                |
| rituximab (Rituxan®)<br>intravenous (IV) infusion | Rheumatoid arthritis (RA)                                                                           | 1,000 mg IV on days 1 and 15 (one course) repeated every 24 weeks or based on clinical evaluation, but no sooner than every 16 weeks; given in combination with methotrexate                                                                                                                                                                                                                               | J9312 | Pediatric idiopathic nephrotic syndrome: 300                                  |
|                                                   | Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or Microscopic polyangiitis (MPA) | <u>Induction (pediatric and adult)</u><br>375 mg/m² IV weekly for 4 doses, <u>or</u> <ul style="list-style-type: none"><li>Pediatric (up to a maximum of 1,000 mg per dose):<ul style="list-style-type: none"><li>575 mg/m² IV on days 1 and 15 (BSA ≤1.5m²)</li><li>750 mg/m² IV on days 1 and 15 (BSA &gt;1.5m²), <u>or</u></li></ul></li><li>Adult: 1,000 mg IV on days 1 and 15 (one course)</li></ul> |       | WAS: 100 (one-time, single-dose per lifetime)<br><br>All other diagnoses: 600 |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| FDA Label Reference |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |       |                |
|---------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------|
| Medication          | Indication              | Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | HCPCS | Maximum Units* |
|                     |                         | <u>Maintenance</u> <ul style="list-style-type: none"> <li>Pediatric: 250 mg/m<sup>2</sup> IV on days 1 and 15, then 250 mg/m<sup>2</sup> every 6 months thereafter based on clinical evaluation</li> <li>Adult: 500 mg to 1,000 mg IV on days 1 and 15, then 500 mg to 1,000 mg every 6 months thereafter based on clinical evaluation</li> </ul> <p>*Initial <u>maintenance</u> infusions should be no sooner than 16 weeks and no later than 24 weeks after the previous infusion if rituximab was used for initial induction therapy.</p> <p>*Initial <u>maintenance</u> infusions should be initiated within 4 weeks following disease control when initial induction occurred with other standard of care immunosuppressants.</p> |       |                |
|                     | Pemphigus vulgaris (PV) | <u>Initiation</u><br>1,000 mg IV on days 1 and 15, <u>or</u> 375 mg/m <sup>2</sup> IV weekly for 4 doses<br><br><u>Maintenance</u><br>500 mg IV at month 12 and repeat every 6 months thereafter or based on clinical evaluation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |       |                |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| FDA Label Reference                                   |                                                                                                          |                                                                                                                                                                                                                                                    |       |                                                                                                                                   |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------------------------------------------------------------------------------------------------------------------------------|
| Medication                                            | Indication                                                                                               | Dosing                                                                                                                                                                                                                                             | HCPCS | Maximum Units*                                                                                                                    |
|                                                       |                                                                                                          | <u>Relapse</u><br>1,000 mg IV upon relapse, resumption of glucocorticoids may be considered<br><br>*Subsequent infusions (maintenance and relapse) should be no sooner than 16 weeks after the previous infusion                                   |       |                                                                                                                                   |
|                                                       | Autoimmune hemolytic anemia (AIHA)                                                                       | <u>Warm-reactive disease</u><br>375 mg/m <sup>2</sup> IV weekly for 4 doses every 6 months, <u>or</u> 1,000 mg on days 1 and 15 every 6 months<br><br><u>Cold agglutinin disease</u><br>375 mg/m <sup>2</sup> IV weekly for 4 doses every 6 months |       |                                                                                                                                   |
| rituximab-arrx (Riabni®)<br>intravenous (IV) infusion | Immune (idiopathic) thrombocytopenia (ITP, Evans syndrome) or Thrombotic thrombocytopenic purpura (iTTP) | 375 mg/m <sup>2</sup> IV weekly for 4 doses every 6 months, <u>or</u> 1,000 mg IV on days 1 and 15 every 6 months                                                                                                                                  | Q5123 | Pediatric idiopathic nephrotic syndrome: 300<br><br>WAS: 100 (one-time, single-dose per lifetime)<br><br>All other diagnoses: 600 |
|                                                       | Multiple sclerosis (MS)                                                                                  | 1,000 mg IV on days 1 and 15, repeat every 6 months                                                                                                                                                                                                |       |                                                                                                                                   |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| FDA Label Reference                                     |                                                            |                                                                                                                                                                                                                                                                                    |       |                                                                                                                                   |
|---------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------------------------------------------------------------------------------------------------------------------------------|
| Medication                                              | Indication                                                 | Dosing                                                                                                                                                                                                                                                                             | HCPCS | Maximum Units*                                                                                                                    |
|                                                         | Neuromyelitis optica spectrum disorder (NMOSD)             | 1,000 mg IV once on days 1 and 15, repeat every 6 months; <u>or</u> 375 mg/m <sup>2</sup> once weekly for 4 weeks, repeat every 6 months                                                                                                                                           |       |                                                                                                                                   |
| rituximab-pvvr (Ruxience®)<br>intravenous (IV) infusion | Immunoglobulin G4-related disease (IgG4-RD)                | <u>Induction</u><br>375 mg/m <sup>2</sup> IV once weekly for 1-4 doses, <u>or</u> 1,000 mg IV on days 1 and 15<br><br>*Subsequent infusions (maintenance and relapse) may be administered at either induction schedule above and should be repeated no sooner than every 6 months. | Q5119 | Pediatric idiopathic nephrotic syndrome: 300<br><br>WAS: 100 (one-time, single-dose per lifetime)<br><br>All other diagnoses: 600 |
|                                                         | Refractory generalized myasthenia gravis (gMG)             | 1,000 mg IV on days 1 and 15, may repeat a full or partial course every 6 months; <u>or</u> 375 mg/m <sup>2</sup> IV once weekly for 4 doses, may repeat a full or partial course every 6 months                                                                                   |       |                                                                                                                                   |
|                                                         | Systemic lupus erythematosus (SLE) or Lupus nephritis (LN) | 1,000 mg IV on days 1 and 15 every 6 months, <u>or</u> 375 mg/m <sup>2</sup> IV once weekly for 4 doses every 6 months                                                                                                                                                             |       |                                                                                                                                   |
| rituximab-abbs (Truxima®)                               | Idiopathic (primary) membranous nephropathy                | 375 mg/m <sup>2</sup> IV once weekly for 1-4 doses every 6 months, <u>or</u> 1,000 mg IV on days 1 and 15 every 6 months                                                                                                                                                           | Q5115 | Pediatric idiopathic nephrotic syndrome: 300                                                                                      |

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

| FDA Label Reference       |                                                                      |                                                                                                                                          |        |                                                                               |
|---------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------------|
| Medication                | Indication                                                           | Dosing                                                                                                                                   | HCP/CS | Maximum Units*                                                                |
| intravenous (IV) infusion | Pediatric idiopathic nephrotic syndrome                              | 375 mg/m <sup>2</sup> IV once weekly for 1-4 doses                                                                                       |        | WAS: 100 (one-time, single-dose per lifetime)<br><br>All other diagnoses: 600 |
|                           | Wiskott-Aldrich syndrome (WAS)                                       | 375 mg/m <sup>2</sup> IV as a single dose approximately 22 days prior to etuvetidigene autotemcel administration                         |        |                                                                               |
|                           | Antisynthetase syndrome-related interstitial lung disease (ASyS-ILD) | 1,000 mg IV on days 1 and 15 repeated every 6 months, <u>or</u> 375 mg/m <sup>2</sup> IV once weekly for 4 doses repeated every 6 months |        |                                                                               |

**\*Maximum units allowed for duration of approval**

Other codes that may be applicable to this policy:

Diagnoses that are subject to medical necessity review: D59.10, D59.11, D59.12, D59.13, D59.19, D69.3, D69.41, D82.0, D89.84, G35.A, G36.0, G70.00, G70.01, J84.170, L10.0, M05.00, M05.011, M05.012, M05.019, M05.021, M05.022, M05.029, M05.031, M05.032, M05.039, M05.041, M05.042, M05.049, M05.051, M05.052, M05.059, M05.061, M05.062, M05.069, M05.071, M05.072, M05.079, M05.09, M05.10, M05.111, M05.112, M05.119, M05.30, M05.311, M05.312, M05.319, M05.321, M05.322, M05.329, M05.331, M05.332, M05.339, M05.341, M05.342, M05.349, M05.351, M05.352, M05.359, M05.361, M05.362, M05.369, M05.371, M05.372, M05.379, M05.39, M05.60, M05.611, M05.612, M05.619, M05.621, M05.622, M05.629, M05.631, M05.632, M05.639, M05.641, M05.642, M05.649, M05.651, M05.652, M05.659, M05.661, M05.662, M05.669, M05.671, M05.672, M05.679, M05.69, M05.A, M06.4, M06.80, M06.811, M06.812, M06.819, M06.821, M06.822, M06.829, M06.831, M06.832, M06.839, M06.841, M06.842, M06.849, M06.851, M06.852, M06.859, M06.861, M06.862, M06.869, M06.871, M06.872, M06.879, M06.88, M06.89, M06.9, M08.00, M08.011, M08.012, M08.019, M08.021, M08.022, M08.029, M08.031, M08.032, M08.039, M08.041, M08.042, M08.049, M08.051, M08.052, M08.059, M08.061, M08.062, M08.069, M08.071, M08.072, M08.079, M08.08, M08.09, M08.20, M08.211, M08.212, M08.219, M08.221, M08.222, M08.229, M08.231, M08.232, M08.239, M08.241, M08.242, M08.249, M08.251, M08.252, M08.259, M08.261, M08.262, M08.269, M08.271, M08.272, M08.279, M08.28, M08.29, M08.40, M08.411, M08.412, M08.419, M08.421, M08.422, M08.429, M08.431, M08.432, M08.439, M08.441, M08.442, M08.449, M08.451, M08.452, M08.459, M08.461, M08.462, M08.469, M08.471, M08.472, M08.479, M08.48, M12.00, M12.011, M12.012, M12.019, M12.021, M12.022, M12.029, M12.031, M12.032, M12.039, M12.041, M12.042, M12.049, M12.051, M12.052, M12.059, M12.061, M12.062, M12.069, M12.071, M12.072,

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

M12.079, M12.08, M12.09, M31.19, M31.30, M31.31, M31.7, M32.14, M32.9, M45.A0, M45.A1, M45.A2, M45.A3, M45.A4, M45.A5, M45.A6, M45.A7, M45.A8, M45.AB, M45.0, M45.1, M45.2, M45.3, M45.4, M45.5, M45.6, M45.7, M45.8, M45.9, N04.21

**\*Site of Care Medical Necessity Criteria**

1. For requests for injection or infusion administration in an **inpatient setting**, the injection or infusion may be given if the above medical necessity criteria are met AND the inpatient admission is NOT for the sole purpose of administering the injection or infusion; **OR**
2. For requests for injection or infusion administration in an **outpatient hospital setting**, the injection or infusion may be given if the above medical necessity criteria are met AND ONE of the following must be met:
  - a. History of a severe adverse event following the injection or infusion of the requested medication (i.e., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure); **OR**
  - b. Conditions that cause an increased risk for severe adverse event (i.e., unstable renal function, cardiopulmonary conditions, unstable vascular access); **OR**
  - c. History of mild adverse events that have not been successfully managed through mild pre-medication (e.g., diphenhydramine, acetaminophen, steroids, fluids, etc.); **OR**
  - d. Inability to physically and cognitively adhere to the treatment schedule and regimen complexity; **OR**
  - e. New to therapy, defined as initial injection or infusion OR less than 3 months since initial injection or infusion; **OR**
  - f. Re-initiation of therapy, defined as ONE of the following:
    - i. First injection or infusion after 6 months of no injections or infusions for drugs with an approved dosing interval less than 6 months duration; **OR**
    - ii. First injection or infusion after at least a 1-month gap in therapy outside of the approved dosing interval for drugs requiring every 6 months dosing duration; **OR**
  - g. Requirement of a change in the requested restricted product formulation; **AND**
3. If the Site of Care Medical Necessity Criteria in #1 or #2 above are not met, the injection or infusion will be administered in a **home-based infusion** or physician office setting with or without supervision by a certified healthcare professional.

**References:** all information referenced is from FDA package insert unless otherwise noted below.

1. Anderson H, Sem M, Lund M, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. *Rheumatology*. 2015 Aug;54(8):1420–1428.
2. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Arthritis Rheumatol*. 2019;71(9):1400-1412.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

3. Barnett C, Herbelin L, Dimachkie MM, et al. Measuring clinical treatment response in myasthenia gravis. *Neurol Clin*. 2018 May;36(2):339-353.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Arthritis Rheumatol*. 2021 Aug;73(8):1366-1383.
5. Doyle TJ, Dhillon N, Madan R, et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review. *J Rheumatol*. 2018 Jun;45(6):841-850.
6. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Annals of the Rheumatic Diseases*. 2023;83(1):15-29.
7. Floege J, Gibson KL, et al. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. *Kidney Int*. 2025;107(5S):S241-S289.
8. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res*. 2021;73(7):924-39.
9. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. *Arthritis Rheumatol*. 2024;76(8):1182-1200.
10. Khosroshahi A, Wallace ZS, Crowe JL, et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. *Arthritis Rheumatol*. 2015;67(7):1688-1699.
11. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int*. 2021 Oct;100(4S):S1-S276.
12. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. *Kidney Int*. 2024;105(1S):S1-S69.
13. Maher TM, Tudor VA, Saunders P, et al.; RECITAL Investigators. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. *Lancet Respir Med*. 2023 Jan;11(1):45-54.
14. Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. *Arthritis Res Ther*. 2015;17(1):183.
15. Narayanaswami P, Sanders DB, Wolfe GI, et al. International consensus guidance for management of myasthenia gravis: 2020 update. *Neurology*. 2021;96(3):114-122.
16. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv*. Dec 10 2019;3(23):3829-66.
17. Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. *Arthritis & Rheumatology*. 2025;77(9):1115-1135.

18. Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. *Arthritis Rheumatol*. 2025 Nov;1-26 (Epub ahead of print).
19. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. *Neurology*. 2016;87:419-425.
20. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res*. 2012;64(5):625-639.
21. Singh JA, Saag KG, Bridges SL, Jr., et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26.
22. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis*. 2023 Jan;82(1):3-18. Erratum in: *Ann Rheum Dis*. 2023 Mar;82(3):e76.
23. Trautmann A, Boyer O, Hodson E, et al. International Pediatric Nephrology Association. IPNA clinical practice recommendations for the diagnosis and management of children with steroid sensitive nephrotic syndrome. *Pediatr Nephrol*. 2023 Mar;38(3):877-919.
24. Trautmann A, Vivarelli M, Samuel S, et al. International Pediatric Nephrology Association. IPNA clinical practice recommendations for the diagnosis and management of children with steroid resistant nephrotic syndrome. *Pediatr Nephrol*. 2020 Aug;35(8):1529-1561.
25. Wallace ZS, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. *Arthritis Rheumatol*. 2020;72(1):7–19.
26. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*. 2015;85(2):177-189.
27. Zheng XL, Al-Housni Z, Cataland SR, et al.; International Society on Thrombosis and Haemostasis. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2025 Nov;23(11):3711-3732.
28. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2020 Oct;18(10):2486-2495. Erratum in: *J Thromb Haemost*. 2021 May;19(5):1381.

**Policy Implementation/Update Information:** Criteria and treatment protocols are reviewed annually by the Blue Cross NC P&T Committee, regardless of change. This policy is reviewed in Q1 annually.

October 2026: Criteria change: For SLE indication, reformatted SLE clinical diagnostic criteria to remove reference to ACR classification criteria and adjusted autoantibody positive verbiage to include different antibodies as examples. Replaced required trial and failure of a corticosteroid or immunosuppressive agent and required combination therapy with a standard immunosuppressant regimen for active SLE with the requirement that the patient has active disease while on standard therapy for SLE alone or as combination therapy. Reformatted hydroxychloroquine combination use requirement with no change to intent. For LN indication, reformatted SLE clinical diagnostic criteria to remove reference to ACR classification criteria, removed autoantibody positive requirement, adjusted LN class verbiage, reformatted

hydroxychloroquine combination use requirement with no change to intent, and added requirement not to be used in combination with Lupkynis for the treatment of LN. Added Site of Care medical necessity criteria for all indications. **Policy notification given 8/3/2026 for effective date 10/1/2026.**

July 2026: Criteria change: Added the following non-oncologic indications to policy with associated criteria and required trial and failure of preferred rituximab biosimilar products (i.e., Riabni, Ruxience, and Truxima): granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA) [subtypes of ANCA-associated vasculitis]; moderate to severe pemphigus vulgaris (PV); autoimmune hemolytic anemia (AIHA), including cold agglutinin disease; immune (idiopathic) thrombocytopenia (ITP, Evans syndrome), chronic; immune-mediated or acquired thrombotic thrombocytopenic purpura (iTTP); multiple sclerosis (MS), relapsing forms; neuromyelitis optica spectrum disorder (NMOSD); immunoglobulin G4-related disease (IgG4-RD); generalized myasthenia gravis (gMG), refractory; systemic lupus erythematosus (SLE); lupus nephritis (LN); idiopathic (primary) membranous nephropathy; pediatric idiopathic nephrotic syndrome; Wiskott-Aldrich syndrome; antisynthetase syndrome-related interstitial lung disease. Added applicable dosing and associated maximum units within dosing reference table for each indication. Added associated ICD-10 codes to policy subject to medical necessity review: D59.10, D59.11, D59.12, D59.13, D59.19, D69.3, D69.41, D82.0, D89.84, G35.A, G36.0, G70.00, G70.01, J84.170, L10.0, M05.A (effective 10/1/2025), M31.19, M31.30, M31.31, M31.7, M32.14, M32.9, and N04.21. Changed policy name to "Rituximab (Rituxan) and Rituximab Biosimilars for the Treatment of Non-Oncologic Indications" from "Rituximab for the Treatment of Rheumatoid Arthritis". **Policy notification given 4/2/2026 for effective date 7/1/2026.**

January 2026: Criteria change: Changed requirement for trial and failure of preferred rituximab biosimilar products to include Riabni in addition to existing preferred Ruxience and Truxima; adjusted non-preferred rituximab products to include Rituxan. Adjusted verbiage for methotrexate trial option to indicate that inadequate response to methotrexate includes maximally tolerated dosing for at least 3-months. Listed examples of agents for trial option of other conventional agents used in the treatment of RA and added trial duration for at least 3-months. Added additional allowance within conventional trial verbiage for intolerance/hypersensitivity/contraindication to conventional agents used in the treatment of RA. Adjusted verbiage for required trial and failure of one or more TNF inhibitor to indicate at least one biologic immunomodulator FDA labeled or compendia supported for the treatment of RA for at least 3 months, and added allowance for intolerance/hypersensitivity to at least one biologic immunomodulator for treatment of RA. Added requirements to be prescribed by or in consultation with a specialist, no contraindication to the requested agent, and for hepatitis B screening. Other formatting changes made throughout policy and dosing reference table for clarity. **Policy notification given 11/1/2025 for effective date 1/1/2026.**

September 2024: Criteria change: Updated requirement for use of preferred rituximab biosimilars (Truxima and Ruxience) prior to Rituxan or non-preferred rituximab biosimilars to also allow for trial and failure of both preferred rituximab biosimilars OR presence of an intolerance, FDA labeled contraindication, or hypersensitivity to all preferred rituximab biosimilar products that is NOT expected to occur with the requested product. Updated references.

October 2021: Coding update: Added the following applicable diagnosis codes to policy effective 10/1/2021: M45.A0, M45.A1, M45.A2, M45.A3, M45.A4, M45.A5, M45.A6, M45.A7, M45.A8, and M45.AB.

July 2021: Coding update: Added HCPCS code Q5123 to dosing reference table effective 7/1/2021, deleted non-specific codes C9399, J3490, and J3590 termed 6/30/2021.

June 2021: Criteria change: Medical record documentation required for trial and failure of preferred and conventional agents.

June 2021: Criteria change: Added maximum units; medical policy formatting change. **Policy notification given 4/16/2021 for effective date 6/16/2021.**

\*Further historical criteria changes and updates available upon request from Medical Policy and/or Corporate Pharmacy.